1 / 22

Bandung, 9 December 2012

Novartis Indonesia Commit to increase accessibility of innovative medicine to more Indonesian Dr Luthfi Mardiansyah CPO Head & Country President Novartis Group Indonesia. Bandung, 9 December 2012.

jdrucker
Télécharger la présentation

Bandung, 9 December 2012

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Novartis IndonesiaCommit to increase accessibility of innovative medicine to more IndonesianDr Luthfi MardiansyahCPO Head & Country PresidentNovartis Group Indonesia Bandung, 9 December 2012

  2. Novartis Group : Basel - SwitzerlandWin through Science-based innovation, in high growth segments of health care Environment Patient needs Novartis Innovative medicines Prevention Affordable options Self-care Pharmaceuticals Eye care (Alcon) Full range of healthcare options Generics(Sandoz) Consumer Health (OTC, Animal Health) Vaccines and Diagnostics

  3. We have a broad healthcare portfolioFocus to meets the varied and often complex needs of patients 2010 net sales by segment Pharmaceuticals Innovative patent-protected medicines V&D Consumer Health Alcon Global leader in eye care with surgical, ophthalmology and vision care Sandoz Affordable, high-quality generic medicines and bio-similars Sandoz Consumer Health Strong, trustworthy brands for knowledgeable consumers: OTC (Over-the-Counter), Animal Health Alcon, Inc.1 Pharmaceuticals Vaccines and Diagnostics Vaccines and diagnostic tools to protect against life-threatening diseases 1 Since August 25, 2010 consolidation 3 | Novartis Indonesia - ITB

  4. Our focus is on patients Our purpose is to care and cure. We provide medicines to treat and prevent diseases, ease suffering and improve quality of life. 4 | Novartis Indonesia - ITB

  5. Fortune – World’s Most Admired Companies 2012Novartis in top three positions over 8 years The 10 most admired pharmaceutical companies

  6. Pharmaceutical Sales and Market Share Worldwide Novartis AG is projected to lead the global market in 2016-2018

  7. 2011 R&D Spending of Top20 CompaniesNovartis No.2 accross the industries and No.1 in Pharma Source: Bloomberg data, Booz & Company Source: 2012 Booz & Company Inc.

  8. Our Commitment to R&DNovartis has continuously moved up in R&D investment ranking Headquarters: Industry: Switzerland Health 2011 R&D Spend: Revenue: USD USD 9.6 bn 58.6 bn Novartis Ranking by R&D spend Source: 2012 Booz & Company Inc.

  9. The Research and Development ProcessTake an averages of 10-15 years in developing a new medicines

  10. More than 3,000 Medicines were in Development in 2011

  11. Pharmaceutical Market in Indonesia

  12. Pharmaceutical Market OverviewPharmaceutical business is a dynamic industry – huge potential • Double Digit Growth • Indonesia’s pharmaceutical market was valued at around USD 5,1bn in 2012 with double digit growth . Increased by 12% from 2011 USD 20/Capita • The increase was driven by Ethical business with 59% market share. This increase driven by generic entry after patent expiry of some molecules • By 2019, prescription medicines are forecasted to reach almost USD6.12bn • Universal Coverage 2014 • After delaying about 2 years, the draft Law on Social Security Administering Bodies (BPJS) agreed in 2011 • PT. ASKES will be prepared to transform into BPJS by 2014. BPJS is a non-profit public institution who is directly reporting to President • Government is pushing the implementation of SJSN (63% coverage in 2014, 100% in 2019) • JAMKESMAS will start to manage under ASKES in 2013 • Premium for poor people and informal sector Rp 22,201 while for formal sector will be 5% person 12 | Novartis Indonesia - ITB

  13. Pharmaceutical Market OverviewOpportunities vs Challenges Opportunities • UHC implementation  large potential market • Positive GDP growth • Double digit growthand outlook remain positive • Increase disease knowledge among Indonesian • Better healthcare infrastructure across the nation Challenges • Healthcare spending is low (<5% of GDP) • Over regulated industry • Regulation from different ministries are non-complementary each other • Limited capabilities in drug production • R&D is not fully developed  lack of incentives • Drug perceives as the most expensive health expenditure 13 | Company Presentation | Corporate Communications | February 2009 | Business Use Only | Business Use Only

  14. Overcoming challenges in the marketHow Pharmaceutical Industry contribute in shaping the environment 14 | Company Presentation | Corporate Communications | February 2009 | Business Use Only | Business Use Only

  15. NOVARTIS INDONESIA - Highest Growth MNC Rank #3 in 2011 – YTD Oct 2012 Pharmaceutical-Rx Market 2011 (IDR Bio) Growth 12.6% -9.7% 26.1% 10.6% 15.1% 5.1% 6.8% 12.2% 4.7% - 5.4% Source: IPMG

  16. How Novartis Helps Patients’ Access to Innovative Drugs?

  17. WHO Framework on The Access to Medication

  18. Novartis focus on Accessibility and Affordability Accessibility • Patients access program for CML patients through GIPAP & NOA program • Treatment accessibility for patients with LEPRA – cooperation with WHO in some centers such as SINTANALA hospital • Education and compliance program with cost sharing for DEMENTIA patients Affordability • Novartis product is available in government insurance, ASKES and JAMKESMAS 18 | Novartis Indonesia - ITB Disclaimer: All the information presented is for healthcare practitioner purposes only.

  19. NITD-Hasanuddin Clinical Research Initiatives Helping to Fight the Tropical Disease Novartis Institute for Tropical Diseases inaugurates new clinical research initiatives in Indonesia called the NITD – Hasanuddin University Clinical Research Initiates (NHCRI) • The institute to study dengue fever, tuberculosis and malaria • Partnership with Hassanudin University will expand NITD’s research capabilities and expertise • Alliance will drive clinical research to explore novel approaches for the treatment of dengue fever, tuberculosis and malaria • New laboratories in Makassar will conduct patients studies in epidemiology, diagnostics, biomarker technologies and novel drug candidates 19 | Novartis Indonesia - ITB

  20. SEHATiBersama, Sehatkan Indonesia!Enlarge its organization, increase its contribution to Indonesia SEHATi BERSAMA actualizes in 3 sub program: SEHATi Berbakti: • Our commitment which realized through its dedication for more than 30 years in providing innovative treatment for Indonesian • In 2011, Novartis launches new innovative treatment for Diabetes, Osteoporosis, Malaria, COPD and wet AMD SEHATi Bersinergi • Actualizes in a form of spirit to synergize with all stakeholders through several initiative: • Clinical trial phase 3 & 4 in Indonesia to discover new treatment. This initiative provides opportunity for knowledge transfer • Partnerships with related stakeholders to improve access and affordability to the innovative treatments SEHATi Berkinerja: • Actualize by delivering excellent performance to achieve positive growth in Indonesia (No.1 by 2016) • Provide more career opportunities for talented Indonesian • Provides human resource development in pharmaceuticals and biotechnology industries 20 | Novartis Indonesia - ITB

  21. Thank you

  22. Background dr. Luthfi Mardiansyah • Chairman – International Pharmaceutical Manufacturers Group (2009-present) • Vice Chairman – EuroCham (2011-present) Professional experiences: • President Director PT Novartis Indonesia, 2011 - current • President Director PT Pfizer Indonesia, 2008-2010 • Sales Director PT Pfizer Indonesia, 2007-2008 • General Manager Capsugel China, 2002-2007 • General Manager Capsugel Indonesia, 1997-2001 • GM In’t Division Indofood, 1994-1997 Educational background: • Medical Dept. Trisakti University, Jakarta, 1987 • LPPM Jakarta – 1989 • Michigan Business School – 2001 • Macquarie Graduate School of Management - 2003 22 | Company Presentation | Corporate Communications | Dec 2012 | Business Use Only | Business Use Only

More Related